TLR4 and atherosclerosis: Because TLR involvement in CVD progression, in particular atherosclerosis, is well established (Ionita et al., 2010; Roshan et al., 2016; Bezhaeva et al., 2022), we have limited our analysis to DAMPs that are described as agonists of at least one TLR, e.g., Calprotectin, a TLR4 ligand.